Archive:
Jan 20, 2025, 12:00 AM
Comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma
Background: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adj…
High variability in diagnoses highlights diagnostic challenges of early-stage melanomas and a need to reconsider how ground truth is established in routine care and AI research
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images …